Among the most frequently reported adverse events described for passive anti-PD-L1 antibodies are endocrine disorders (thyroid diseases such as hypothyroidism and hyperthyroidism, followed by pituitary and adrenal dysfunction), gastrointestinal symptoms (diarrhea, colitis, and nausea), pulmonary symptoms (pneumonia), skin symptoms (rash, pruritus, and leukoplakia), and musculoskeletal symptoms (arthralgia and myalgia). This evidence concerns the gene CD274 and colitis.